v3.25.2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 8,028	$ 11,973
Trade receivables, net	8,701	6,782
Inventories	6,583	6,998
Other current assets	3,422	3,277
Total current assets	26,734	29,030
Property, plant and equipment, net	6,855	6,543
Intangible assets, net	24,614	27,699
Goodwill	18,674	18,637
Other noncurrent assets	11,020	9,930
Total assets	87,897	91,839
Current liabilities:
Accounts payable	3,010	1,908
Accrued liabilities	15,022	17,641
Current portion of long-term debt	2,444	3,550
Total current liabilities	20,476	23,099
Long-term debt	53,760	56,549
Long-term deferred tax liabilities	1,386	1,616
Long-term tax liabilities	2,511	2,349
Other noncurrent liabilities	2,336	2,349
Contingencies and commitments (see Note 13)
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—538.3 shares in 2025 and 536.9 shares in 2024	33,680	33,533
Accumulated deficit	(25,708)	(27,590)
Accumulated other comprehensive loss	(544)	(66)
Total stockholders’ equity	7,428	5,877
Total liabilities and stockholders’ equity	$ 87,897	$ 91,839

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

AMGEN INC 10-Q